{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T06:53:20Z","timestamp":1791010400795,"version":"4.1.0"},"reference-count":44,"publisher":"Wiley","license":[{"start":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T00:00:00Z","timestamp":1790899200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T00:00:00Z","timestamp":1790899200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Br J Clin Pharmacol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>Tedizolid is a next\u2010generation oxazolidinone antibiotic approved for the treatment of acute bacterial skin and skin structure infections (ABSSSIs). This study aimed to develop a physiologically based pharmacokinetic (PBPK) model for tedizolid in adults and paediatric population.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      An adult PBPK model was built using GastroPlus\u00ae, incorporating physicochemical and pharmacokinetic parameters from the literature. The model was verified against clinical PK data from healthy adults and patients. It was then scaled to paediatric patients aged 2\u201318\u2009years using age\u2010dependent physiological changes. Paediatric model performance was validated against independent clinical data. Dose simulations evaluated once\u2010daily intravenous and oral regimens targeting a free\u2010drug area under the plasma concentration\u2013time curve (AUC)\/minimum inhibitory concentration (MIC) ratio (\n                      <jats:italic>f<\/jats:italic>\n                      AUC\/MIC) of \u22653, with \u226590% probability of target attainment (PTA) across MIC values of 0.125\u201316\u2009mg\/L in immunocompetent patients.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The adult and paediatric PBPK models showed good predictive performance, with all predicted AUC and\n                      <jats:italic>C<\/jats:italic>\n                      <jats:sub>max<\/jats:sub>\n                      values within the acceptable twofold error range and most observed concentrations falling within the 90% prediction interval. For children aged 2 to &lt;12\u2009years, intravenous and oral doses of \u22654\u2009mg\/kg achieved \u226590% PTA at an MIC of 0.5\u2009mg\/L. For adolescents aged 12 to &lt;18\u2009years, either a fixed 200\u2009mg dose or a 3\u2009mg\/kg dose (intravenous or oral) achieved \u226590% PTA at an MIC of 0.5\u2009mg\/L.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The paediatric PBPK model was successfully developed and identified model\u2010derived candidate regimens for immunocompetent paediatric patients with ABSSSIs. These findings support further clinical evaluation of PBPK\u2010guided dose optimization in children.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/bcp.70845","type":"journal-article","created":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T06:25:45Z","timestamp":1791008745000},"source":"Crossref","is-referenced-by-count":0,"title":["Physiologically based pharmacokinetic modelling and dose optimization of tedizolid in paediatric patients"],"prefix":"10.1002","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4064-3735","authenticated-orcid":false,"given":"Xueyong","family":"Li","sequence":"first","affiliation":[{"name":"Department of Pharmacy Fujian Medical University Union Hospital  Fuzhou Fujian China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Cheng","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Fujian Medical University Union Hospital  Fuzhou Fujian China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rongqi","family":"Lin","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Shanghang County Hospital  Shanghang Fujian China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingping","family":"Shao","sequence":"additional","affiliation":[{"name":"Faculty of Pharmacy Zhejiang Pharmaceutical University  Ningbo Zhejiang China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luqi","family":"Lou","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Fujian Medical University Union Hospital  Fuzhou Fujian China"},{"name":"The School of Pharmacy Fujian Medical University  Fuzhou Fujian China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tian","family":"Lin","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Fujian Medical University Union Hospital  Fuzhou Fujian China"},{"name":"The School of Pharmacy Fujian Medical University  Fuzhou Fujian China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1640-7385","authenticated-orcid":false,"given":"Xuemei","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Fujian Medical University Union Hospital  Fuzhou Fujian China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongqing","family":"Qiu","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Fujian Medical University Union Hospital  Fuzhou Fujian China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,10,2]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2018.1446939"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265\u2010015\u20100352\u20107"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00663\u201010"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.03423\u201014"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1002\/phar.1458"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpdd.426"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2017.08.002"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.03431\u201014"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm7060150"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00682\u201016"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40262\u2010021\u201001099\u20107"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1002\/phar.1491"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2012.03.006"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.05354\u201011"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.113.056697"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cit615"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01565\u201010"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00502\u201011"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1097\/INF.0000000000001096"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1097\/INF.0000000000003030"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.semperi.2015.08.007"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11095\u2010022\u201003274\u20102"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1208\/s12249\u2010021\u201002076\u2010w"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.1002\/psp4.12134"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.1002\/jps.10128"},{"key":"e_1_2_10_27_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40121\u2010015\u20100060\u20103"},{"key":"e_1_2_10_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejpb.2020.08.006"},{"key":"e_1_2_10_29_1","doi-asserted-by":"publisher","DOI":"10.1208\/s12248\u2010009\u20109088\u20101"},{"key":"e_1_2_10_30_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003088\u2010200645090\u201000005"},{"key":"e_1_2_10_31_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003088\u2010200645100\u201000005"},{"key":"e_1_2_10_32_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00467\u2010008\u20100997\u20105"},{"key":"e_1_2_10_33_1","doi-asserted-by":"publisher","DOI":"10.15620\/cdc\/174595"},{"key":"e_1_2_10_34_1","first-page":"1","article-title":"2000 CDC growth charts for the United States: methods and development","volume":"246","author":"Kuczmarski RJ","year":"2002","journal-title":"Vital Health Stat 11"},{"key":"e_1_2_10_35_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkr403"},{"key":"e_1_2_10_36_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkw206"},{"key":"e_1_2_10_37_1","doi-asserted-by":"publisher","DOI":"10.1208\/s12248\u2010020\u20100423\u2010x"},{"key":"e_1_2_10_38_1","doi-asserted-by":"publisher","DOI":"10.1002\/phar.2703"},{"key":"e_1_2_10_39_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.119.086462"},{"key":"e_1_2_10_40_1","doi-asserted-by":"publisher","DOI":"10.2174\/138920008783571819"},{"key":"e_1_2_10_41_1","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S525400"},{"key":"e_1_2_10_42_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40262\u2010024\u201001367\u20102"},{"key":"e_1_2_10_43_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01303\u201012"},{"key":"e_1_2_10_44_1","unstructured":"Merck Sharp & Dohme LLC.SIVEXTRO (tedizolid phosphate) tablets for oral use; SIVEXTRO (tedizolid phosphate) for injection for intravenous use. Full Prescribing Information.Merck Sharp & Dohme LLC2025. Accessed [date].https:\/\/www.accessdata.fda.gov\/scripts\/cder\/daf\/index.cfm?event=overview.process&ApplNo=205435. Accessed 30 Mar 2026"},{"key":"e_1_2_10_45_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jgar.2024.11.011"}],"container-title":["British Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/bcp.70845","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/bcp.70845","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/bcp.70845","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T06:25:47Z","timestamp":1791008747000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1002\/bcp.70845"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,2]]},"references-count":44,"alternative-id":["10.1002\/bcp.70845"],"URL":"https:\/\/doi.org\/10.1002\/bcp.70845","archive":["Portico"],"relation":{},"ISSN":["0306-5251","1365-2125"],"issn-type":[{"value":"0306-5251","type":"print"},{"value":"1365-2125","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,2]]},"article-number":"bcp.70845"}}